Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 08, 2024 05:45 ET | Source: BioNTech SE

BioNTech und Autolus schließen strategische Kollaboration zur Weiterentwicklung der Pipeline und Ausbau fortgeschrittener CAR-T-Zelltherapie-Programme

Die Unternehmen nutzen in der strategischen Zusammenarbeit Produktionskapazitäten, kommerzielle Infrastruktur sowie Technologien mit dem Ziel, die autologen CAR-T-Programme beider Unternehmen...
February 08, 2024 05:45 ET | Source: BioNTech SE

BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market...
May 02, 2022 16:31 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present Three Novel Cell Programming Approaches at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting, May 16-19, 2022

LONDON, May 02, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...
April 25, 2022 07:01 ET | Source: Autolus Therapeutics plc

FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
April 25, 2022 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Report First Quarter 2022 Financial Results and Host Conference Call on May 5

LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
March 29, 2022 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Participate in Conferences During April 2022

- Wells Fargo Annual Biotech Forum on April 12 and 13 - - 21st Annual Needham Virtual Healthcare Conference on April 14 at 8:45am ET - - 14th Kempen Life Sciences Conference on April 21 -...
November 04, 2021 09:01 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present New Data at the 63rd ASH Annual Meeting & Exposition

- Demonstrates progress on the Company’s commercial manufacturing process and builds on positive obe-cel clinical data presented at EHA Conference Call and Webcast to be held Tuesday, December 14,...
October 25, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Report Third Quarter 2021 Financial Results and Host Conference Call on November 3

LONDON, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
April 20, 2021 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 (TRBC1) positive T cell lymphomas

LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
September 08, 2020 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September

LONDON, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

Next Page keyboard_arrow_right